Wedbush Reaffirms Ovid Therapeutics At Outperform With Price Target Of $7

Wedbush reiterated Ovid Therapeutics (OVID) at an Outperform rating with a $7 price target. Analyst Laura Chico highlighted the KCC2 R&D Event on April 14, 2026 as an important upcoming catalyst. The note is a modestly positive signal for OVID ahead of the event but is unlikely to move broader markets; it may affect the stock around the R&D update.

Analysis

Wedbush reiterated Ovid Therapeutics (OVID) at an Outperform rating with a $7 price target. Analyst Laura Chico highlighted the KCC2 R&D Event on April 14, 2026 as an important upcoming catalyst. The note is a modestly positive signal for OVID ahead of the event but is unlikely to move broader markets; it may affect the stock around the R&D update.